You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNiflumic Acid
Accession NumberDB04552  (EXPT02331)
TypeSmall Molecule
GroupsApproved
DescriptionAn analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis. [PubChem]
Structure
Thumb
Synonyms
Acide niflumique
Acido niflumico
Acidum niflumicum
NFA
Niflugel
External Identifiers
  • Lopac-N-0630
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
NiflamNot Available
NiflugelNot Available
NiflurilNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII4U5MP5IUD8
CAS number4394-00-7
WeightAverage: 282.218
Monoisotopic: 282.061612157
Chemical FormulaC13H9F3N2O2
InChI KeyJZFPYUNJRRFVQU-UHFFFAOYSA-N
InChI
InChI=1S/C13H9F3N2O2/c14-13(15,16)8-3-1-4-9(7-8)18-11-10(12(19)20)5-2-6-17-11/h1-7H,(H,17,18)(H,19,20)
IUPAC Name
2-{[3-(trifluoromethyl)phenyl]amino}pyridine-3-carboxylic acid
SMILES
OC(=O)C1=C(NC2=CC=CC(=C2)C(F)(F)F)N=CC=C1
Pharmacology
IndicationUsed in the treatment of rheumatoid arthritis.
Structured Indications Not Available
PharmacodynamicsNiflumic acid, a nonsteroidal anti-inflammatory fenamate, is a Ca2+-activated Cl- channel blocker.
Mechanism of actionNiflumic acid is able to inhibit both phospholipase A2 as well as COX-2, thereby acting as an antiinflamatory and pain reduction agent.
TargetKindPharmacological actionActionsOrganismUniProt ID
Phospholipase A2Proteinyes
inhibitor
HumanP04054 details
Prostaglandin G/H synthase 2Proteinyes
inhibitor
HumanP35354 details
Chloride channel protein ClC-KaProteinunknown
inducer
HumanP51800 details
Prostaglandin G/H synthase 1ProteinunknownNot AvailableHumanP23219 details
Cytosolic phospholipase A2ProteinunknownNot AvailableHumanP47712 details
UDP-glucuronosyltransferase 1-9ProteinunknownNot AvailableHumanO60656 details
Related Articles
AbsorptionWell absorbed following oral administration.
Volume of distributionNot Available
Protein binding90% bound to plasma proteins.
Metabolism

Hepatic.

Route of eliminationNot Available
Half life2.5 hours
ClearanceNot Available
ToxicityOral, mouse: LD50 = 350 mg/kg; Oral, rat: LD50 = 250 mg/kg
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with 5-androstenedione.Experimental, Illicit
AbciximabNiflumic Acid may increase the anticoagulant activities of Abciximab.Approved
AcebutololNiflumic Acid may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Aceclofenac.Approved
AcenocoumarolNiflumic Acid may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Niflumic Acid.Approved, Vet Approved
AclarubicinNiflumic Acid may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Niflumic Acid.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Alendronic acid.Approved
AliskirenNiflumic Acid may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololNiflumic Acid may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Niflumic Acid.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Amcinonide.Approved
AmikacinNiflumic Acid may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideNiflumic Acid may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinNiflumic Acid may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodNiflumic Acid may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Anisodamine.Investigational
annamycinNiflumic Acid may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Niflumic Acid.Approved
Antithrombin III humanNiflumic Acid may increase the anticoagulant activities of Antithrombin III human.Approved
Aop200704Niflumic Acid may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanNiflumic Acid may increase the anticoagulant activities of Apixaban.Approved
ApramycinNiflumic Acid may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Apremilast.Approved, Investigational
ArbekacinNiflumic Acid may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinNiflumic Acid may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanNiflumic Acid may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololNiflumic Acid may decrease the antihypertensive activities of Arotinolol.Approved
AtenololNiflumic Acid may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Niflumic Acid.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Niflumic Acid.Approved
BalsalazideNiflumic Acid may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminNiflumic Acid may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololNiflumic Acid may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Niflumic Acid.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Niflumic Acid.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Benoxaprofen.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Niflumic Acid.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Betamethasone.Approved, Vet Approved
BetaxololNiflumic Acid may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Betulinic Acid.Investigational
BevantololNiflumic Acid may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Niflumic Acid.Approved, Investigational
BisoprololNiflumic Acid may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinNiflumic Acid may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololNiflumic Acid may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Niflumic Acid.Approved
BucillamineThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Bucillamine.Investigational
BucindololNiflumic Acid may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Budesonide.Approved
BufuralolNiflumic Acid may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideNiflumic Acid may decrease the diuretic activities of Bumetanide.Approved
BupranololNiflumic Acid may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Niflumic Acid.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Niflumic Acid.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Niflumic Acid.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Niflumic Acid.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Niflumic Acid.Approved, Vet Approved, Withdrawn
CarteololNiflumic Acid may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolNiflumic Acid may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Niflumic Acid.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Celecoxib.Approved, Investigational
CeliprololNiflumic Acid may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinNiflumic Acid may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Niflumic Acid.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Niflumic Acid.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Niflumic Acid.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Niflumic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Niflumic Acid.Approved
CinoxacinNiflumic Acid may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinNiflumic Acid may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
Citric AcidNiflumic Acid may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Niflumic Acid.Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Niflumic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Niflumic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Curcumin.Investigational
CyclosporineNiflumic Acid may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with D-Limonene.Investigational
Dabigatran etexilateNiflumic Acid may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinNiflumic Acid may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidNiflumic Acid may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DaunorubicinNiflumic Acid may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with dehydroepiandrosterone sulfate.Investigational
DesirudinNiflumic Acid may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Niflumic Acid.Approved
DextranNiflumic Acid may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Niflumic Acid may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Niflumic Acid may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Niflumic Acid may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Niflumic Acid.Approved, Vet Approved
DicoumarolNiflumic Acid may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Niflumic Acid.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Niflumic Acid.Approved
DihydrostreptomycinNiflumic Acid may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Niflumic Acid.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Niflumic Acid.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Niflumic Acid.Approved
DoxorubicinNiflumic Acid may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneNiflumic Acid may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Niflumic Acid is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Ebselen.Investigational
Edetic AcidNiflumic Acid may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanNiflumic Acid may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Niflumic Acid.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Niflumic Acid.Approved
EnoxacinNiflumic Acid may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinNiflumic Acid may increase the anticoagulant activities of Enoxaparin.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Epirizole.Approved
EpirubicinNiflumic Acid may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneNiflumic Acid may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Niflumic Acid.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Niflumic Acid.Approved
EquileninThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Equilin.Approved
EsmololNiflumic Acid may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Estrone sulfate.Approved
Etacrynic acidNiflumic Acid may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Niflumic Acid.Approved, Investigational
Ethyl biscoumacetateNiflumic Acid may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with exisulind.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Niflumic Acid.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Niflumic Acid.Vet Approved
FleroxacinNiflumic Acid may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Niflumic Acid.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fludrocortisone.Approved
FluindioneNiflumic Acid may increase the anticoagulant activities of Fluindione.Investigational
FlumequineNiflumic Acid may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Flunixin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Niflumic Acid.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Niflumic Acid.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fluticasone Propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Niflumic Acid.Approved, Nutraceutical, Vet Approved
FondaparinuxNiflumic Acid may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumNiflumic Acid may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Niflumic Acid.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Niflumic Acid.Approved
FramycetinNiflumic Acid may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideNiflumic Acid may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateNiflumic Acid may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinNiflumic Acid may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinNiflumic Acid may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Niflumic Acid.Approved, Withdrawn
GemifloxacinNiflumic Acid may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinNiflumic Acid may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinNiflumic Acid may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ANiflumic Acid may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GrepafloxacinNiflumic Acid may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Niflumic Acid is combined with HE3286.Investigational
HeparinNiflumic Acid may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Higenamine.Investigational
HirulogNiflumic Acid may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when Niflumic Acid is combined with HMPL-004.Investigational
HydralazineNiflumic Acid may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Niflumic Acid.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Niflumic Acid.Approved
Hygromycin BNiflumic Acid may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Niflumic Acid.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Icatibant.Approved
IdarubicinNiflumic Acid may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
idraparinuxNiflumic Acid may increase the anticoagulant activities of idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Niflumic Acid.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Niflumic Acid.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Niflumic Acid.Approved
IndenololNiflumic Acid may decrease the antihypertensive activities of Indenolol.Withdrawn
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Niflumic Acid.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Indoprofen.Withdrawn
INNO-206Niflumic Acid may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Niflumic Acid.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Istaroxime.Investigational
KanamycinNiflumic Acid may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Niflumic Acid.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Niflumic Acid.Approved
LabetalolNiflumic Acid may decrease the antihypertensive activities of Labetalol.Approved
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Niflumic Acid.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Niflumic Acid.Approved, Investigational
LepirudinNiflumic Acid may increase the anticoagulant activities of Lepirudin.Approved
LevobunololNiflumic Acid may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinNiflumic Acid may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Niflumic Acid.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Niflumic Acid.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Niflumic Acid.Approved
LomefloxacinNiflumic Acid may increase the neuroexcitatory activities of Lomefloxacin.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Niflumic Acid.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Niflumic Acid.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Niflumic Acid.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Niflumic Acid.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Niflumic Acid.Approved
ME-609The risk or severity of adverse effects can be increased when Niflumic Acid is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Niflumic Acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Niflumic Acid.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Niflumic Acid.Approved, Vet Approved
MesalazineNiflumic Acid may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Metamizole.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Niflumic Acid.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Niflumic Acid.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Methylprednisolone.Approved, Vet Approved
MetipranololNiflumic Acid may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Niflumic Acid.Approved
MetoprololNiflumic Acid may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideNiflumic Acid may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Niflumic Acid.Approved
MizoribineThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Niflumic Acid.Approved
MometasoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Niflumic Acid.Approved
MoxifloxacinNiflumic Acid may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Niflumic Acid.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Niflumic Acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Nabumetone.Approved
NadololNiflumic Acid may decrease the antihypertensive activities of Nadolol.Approved
NadroparinNiflumic Acid may increase the anticoagulant activities of Nadroparin.Approved
NafamostatNiflumic Acid may increase the anticoagulant activities of Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Niflumic Acid.Approved
Nalidixic AcidNiflumic Acid may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Niflumic Acid.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Niflumic Acid is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when Niflumic Acid is combined with NCX 4016.Investigational
NeamineNiflumic Acid may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinNiflumic Acid may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinNiflumic Acid may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Nepafenac.Approved
NetilmicinNiflumic Acid may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NimesulideThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Nimesulide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Nitroaspirin.Investigational
NorfloxacinNiflumic Acid may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinNiflumic Acid may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Niflumic Acid.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Niflumic Acid.Approved
OlsalazineNiflumic Acid may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Niflumic Acid.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Orgotein.Vet Approved
OtamixabanNiflumic Acid may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Niflumic Acid.Approved
OxprenololNiflumic Acid may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Niflumic Acid.Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Parecoxib.Approved
ParomomycinNiflumic Acid may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PazufloxacinNiflumic Acid may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinNiflumic Acid may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololNiflumic Acid may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateNiflumic Acid may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Niflumic Acid.Approved
PhenindioneNiflumic Acid may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonNiflumic Acid may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Niflumic Acid.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Niflumic Acid.Approved, Investigational
PindololNiflumic Acid may decrease the antihypertensive activities of Pindolol.Approved
PirarubicinNiflumic Acid may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideNiflumic Acid may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Pirfenidone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Niflumic Acid.Approved, Investigational
PlicamycinNiflumic Acid may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Niflumic Acid.Approved
PractololNiflumic Acid may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Niflumic Acid.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Prasterone.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Pregnenolone.Experimental
ProbenecidThe serum concentration of Niflumic Acid can be increased when it is combined with Probenecid.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Propacetamol.Approved
PropranololNiflumic Acid may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Niflumic Acid.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Niflumic Acid.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Niflumic Acid.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Niflumic Acid.Vet Approved
Protein CNiflumic Acid may increase the anticoagulant activities of Protein C.Approved
Protein S humanNiflumic Acid may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeNiflumic Acid may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinNiflumic Acid may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Niflumic Acid is combined with PTC299.Investigational
PuromycinNiflumic Acid may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Niflumic Acid.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Niflumic Acid.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Niflumic Acid.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Niflumic Acid.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Niflumic Acid.Experimental, Investigational
ReviparinNiflumic Acid may increase the anticoagulant activities of Reviparin.Approved
RibostamycinNiflumic Acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Risedronate.Approved, Investigational
RivaroxabanNiflumic Acid may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Rofecoxib.Investigational, Withdrawn
RosoxacinNiflumic Acid may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Niflumic Acid.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Niflumic Acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Niflumic Acid.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Niflumic Acid.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Niflumic Acid.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Seratrodast.Approved, Investigational
SisomicinNiflumic Acid may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SotalolNiflumic Acid may decrease the antihypertensive activities of Sotalol.Approved
SP1049CNiflumic Acid may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinNiflumic Acid may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinNiflumic Acid may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Niflumic Acid.Approved
SpironolactoneNiflumic Acid may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Niflumic Acid is combined with SRT501.Investigational
StreptomycinNiflumic Acid may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinNiflumic Acid may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineNiflumic Acid may increase the nephrotoxic activities of Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Niflumic Acid.Approved
SulodexideNiflumic Acid may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Niflumic Acid.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Niflumic Acid.Approved, Withdrawn
TacrolimusNiflumic Acid may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Niflumic Acid.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Niflumic Acid.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Niflumic Acid.Approved
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Technetium Tc-99m Medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Niflumic Acid.Approved, Investigational
TemafloxacinNiflumic Acid may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Niflumic Acid.Experimental, Investigational
TenofovirThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Niflumic Acid.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Teriflunomide.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Niflumic Acid.Approved
TiludronateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Tiludronate.Approved, Vet Approved
TimololNiflumic Acid may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Tixocortol.Approved
TobramycinNiflumic Acid may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Niflumic Acid.Approved
TorasemideNiflumic Acid may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Niflumic Acid.Approved
TranilastThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Niflumic Acid.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Niflumic Acid.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Triamcinolone.Approved, Vet Approved
TriamtereneNiflumic Acid may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Niflumic Acid.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Niflumic Acid.Approved
TrovafloxacinNiflumic Acid may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Niflumic Acid.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Valdecoxib.Investigational, Withdrawn
ValrubicinNiflumic Acid may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Niflumic Acid.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Niflumic Acid.Approved
WarfarinNiflumic Acid may increase the anticoagulant activities of Warfarin.Approved
XimelagatranNiflumic Acid may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Niflumic Acid may increase the anticoagulant activities of Ym150.Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Niflumic Acid.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Zomepirac.Withdrawn
ZorubicinNiflumic Acid may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Criddle DN, de Moura RS, Greenwood IA, Large WA: Inhibitory action of niflumic acid on noradrenaline- and 5-hydroxytryptamine-induced pressor responses in the isolated mesenteric vascular bed of the rat. Br J Pharmacol. 1997 Mar;120(5):813-8. [PubMed:9138686 ]
External Links
ATC CodesM02AA17M01AX02
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSDownload (73.3 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9298
Blood Brain Barrier+0.9115
Caco-2 permeable+0.5318
P-glycoprotein substrateNon-substrate0.7803
P-glycoprotein inhibitor INon-inhibitor0.8783
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterNon-inhibitor0.9236
CYP450 2C9 substrateNon-substrate0.7654
CYP450 2D6 substrateNon-substrate0.8881
CYP450 3A4 substrateNon-substrate0.776
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.7762
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7812
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.8322
BiodegradationNot ready biodegradable0.992
Rat acute toxicity3.0838 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.988
hERG inhibition (predictor II)Non-inhibitor0.7993
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point203 °CNot Available
water solubility19 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.43TAKACS-NOVAK,K ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0883 mg/mLALOGPS
logP4.33ALOGPS
logP3.12ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)1.88ChemAxon
pKa (Strongest Basic)5.51ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area62.22 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity65.93 m3·mol-1ChemAxon
Polarizability24.21 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (9.79 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as pyridinecarboxylic acids. These are compounds containing a pyridine ring bearing a carboxylic acid group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassPyridinecarboxylic acids and derivatives
Direct ParentPyridinecarboxylic acids
Alternative Parents
Substituents
  • Pyridine carboxylic acid
  • Aminopyridine
  • Imidolactam
  • Benzenoid
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Vinylogous amide
  • Azacycle
  • Secondary amine
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Receptor binding
Specific Function:
PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides, this releases glycerophospholipids and arachidonic acid that serve as the precursors of signal molecules.
Gene Name:
PLA2G1B
Uniprot ID:
P04054
Molecular Weight:
16359.535 Da
References
  1. Jabeen T, Singh N, Singh RK, Sharma S, Somvanshi RK, Dey S, Singh TP: Non-steroidal anti-inflammatory drugs as potent inhibitors of phospholipase A2: structure of the complex of phospholipase A2 with niflumic acid at 2.5 Angstroms resolution. Acta Crystallogr D Biol Crystallogr. 2005 Dec;61(Pt 12):1579-86. Epub 2005 Nov 19. [PubMed:16301791 ]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Jabeen T, Singh N, Singh RK, Sharma S, Somvanshi RK, Dey S, Singh TP: Non-steroidal anti-inflammatory drugs as potent inhibitors of phospholipase A2: structure of the complex of phospholipase A2 with niflumic acid at 2.5 Angstroms resolution. Acta Crystallogr D Biol Crystallogr. 2005 Dec;61(Pt 12):1579-86. Epub 2005 Nov 19. [PubMed:16301791 ]
  2. Diao HL, Zhu H, Ma H, Tan HN, Cong J, Su RW, Yang ZM: Rat ovulation, implantation and decidualization are severely compromised by COX-2 inhibitors. Front Biosci. 2007 May 1;12:3333-42. [PubMed:17485303 ]
  3. Alpert E, Gruzman A, Tennenbaum T, Sasson S: Selective cyclooxygenase-2 inhibitors stimulate glucose transport in L6 myotubes in a protein kinase Cdelta-dependent manner. Biochem Pharmacol. 2007 Feb 1;73(3):368-77. Epub 2006 Oct 13. [PubMed:17098211 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Voltage-gated chloride channel activity
Specific Function:
Voltage-gated chloride channel. Chloride channels have several functions including the regulation of cell volume; membrane potential stabilization, signal transduction and transepithelial transport. May be important in urinary concentrating mechanisms.
Gene Name:
CLCNKA
Uniprot ID:
P51800
Molecular Weight:
75284.08 Da
References
  1. Picollo A, Liantonio A, Babini E, Camerino DC, Pusch M: Mechanism of interaction of niflumic acid with heterologously expressed kidney CLC-K chloride channels. J Membr Biol. 2007 Apr;216(2-3):73-82. Epub 2007 Jul 21. [PubMed:17659402 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Talbot S, Lin JC, Lahjouji K, Roy JP, Senecal J, Morin A, Couture R: Cigarette smoke-induced kinin B1 receptor promotes NADPH oxidase activity in cultured human alveolar epithelial cells. Peptides. 2011 Jul;32(7):1447-56. doi: 10.1016/j.peptides.2011.05.005. Epub 2011 May 11. [PubMed:21600945 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Phospholipase a2 activity
Specific Function:
Selectively hydrolyzes arachidonyl phospholipids in the sn-2 position releasing arachidonic acid. Together with its lysophospholipid activity, it is implicated in the initiation of the inflammatory response.
Gene Name:
PLA2G4A
Uniprot ID:
P47712
Molecular Weight:
85238.2 Da
References
  1. Jabeen T, Singh N, Singh RK, Sharma S, Somvanshi RK, Dey S, Singh TP: Non-steroidal anti-inflammatory drugs as potent inhibitors of phospholipase A2: structure of the complex of phospholipase A2 with niflumic acid at 2.5 Angstroms resolution. Acta Crystallogr D Biol Crystallogr. 2005 Dec;61(Pt 12):1579-86. Epub 2005 Nov 19. [PubMed:16301791 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Molecular Weight:
59940.495 Da
References
  1. Mano Y, Usui T, Kamimura H: In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant human UDP-glucuronosyltransferase 1A9--potent inhibition by niflumic acid. Biopharm Drug Dispos. 2006 Jan;27(1):1-6. [PubMed:16278927 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Symporter activity
Specific Function:
Proton-coupled monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate. Functions as high-affinity pyruvate transporter.
Gene Name:
SLC16A7
Uniprot ID:
O60669
Molecular Weight:
52199.745 Da
References
  1. Broer S, Broer A, Schneider HP, Stegen C, Halestrap AP, Deitmer JW: Characterization of the high-affinity monocarboxylate transporter MCT2 in Xenopus laevis oocytes. Biochem J. 1999 Aug 1;341 ( Pt 3):529-35. [PubMed:10417314 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Symporter activity
Specific Function:
Proton-coupled monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate. Depending on the tissue and on cicumstances, mediates the import or export of lactic acid and ketone bod...
Gene Name:
SLC16A1
Uniprot ID:
P53985
Molecular Weight:
53943.685 Da
References
  1. Broer S, Broer A, Schneider HP, Stegen C, Halestrap AP, Deitmer JW: Characterization of the high-affinity monocarboxylate transporter MCT2 in Xenopus laevis oocytes. Biochem J. 1999 Aug 1;341 ( Pt 3):529-35. [PubMed:10417314 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:24